As­traZeneca sweeps away the Med­Im­mune name as CEO So­ri­ot re­struc­tures R&D

Med­Im­mune is his­to­ry.

As­traZeneca ex­ecs ac­knowl­edged to­day that the com­pa­ny is sweep­ing the Med­Im­mune brand name away as CEO Pas­cal So­ri­ot stream­lines the R&D or­ga­ni­za­tion, carv­ing the group in­to 2 parts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER